Pharma Journalist -

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...

Taysha Gene Therapies announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, its intrathecally delivered AAV9 gene therapy…
Read More...

Halozyme Therapeutics has announced a definitive agreement to acquire Elektrofi, a biopharmaceutical company known for its breakthrough ultra-high concentration biologics delivery…
Read More...

Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company…
Read More...

Star Therapeutics has announced the closing of an oversubscribed $125 million Series D financing round to accelerate the development of its pipeline of antibody-based therapies,…
Read More...

Klotho Neurosciences, Inc. has announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc., a pioneer in cellular reprogramming and induced…
Read More...

Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.'s…
Read More...

AbbVie has broken ground on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, a key hub for the company’s biologics research, development, and…
Read More...

BioLineRx Ltd. and Norwegian biotech Hemispherian AS have established a joint venture to develop GLIX1, a first-in-class oral small molecule designed to target DNA damage response in…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib), an oral treatment for adult patients with chronic spontaneous urticaria (CSU)…
Read More...